Boosting communication between the spinal nerves and the muscles using the spinal cord stimulation reverses spinal muscle atrophy (SMA) progression and could be applied to other motoneuron diseases, ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

Dr. Michael Rezak, MD, Ph.D., DBe, is a renowned neurologist specializing in the treatment of complex movement disorders such as Parkinson's Disease, ...

Claudia Patino Tarlow Claudia Patino Tarlow, of Sag Harbor, died on January 10 after struggling for a decade battling ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

MPs and campaigners say that people suffering from Motor Neurone Disease or Parkinson’s should have greater access to an ...

Other letters look at Medical Aid in Dying, cryptocurrency mining, climate change policies, and national politics ...

In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Brain disease patients with a year to live could choose assisted dying under plans to be considered by MPs next week ...